SCHEMBL7335937

SCHEMBL7335937

NN=Cc1ccc2cc(C(=O)Nc3ccc4ccccc4c3)ccc2c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DEGS1 O15121 1/20 0.57
▸ NPC1 O15118 12/20 0.56
▸ RAB9A P51151 12/20 0.56
▸ MEN1 O00255 8/20 0.56
▸ KMT2A Q03164 8/20 0.56
▸ TDP1 Q9NUW8 1/20 0.56
▸ CASP3 P42574 3/20 0.53
▸ SENP7 Q9BQF6 3/20 0.53
▸ KDM4E B2RXH2 2/20 0.53
▸ L3MBTL1 Q9Y468 1/20 0.53
▸ SENP6 Q9GZR1 1/20 0.53
▸ NQO2 P16083 1/20 0.53
▸ CA12 O43570 1/20 0.52
▸ CA1 P00915 1/20 0.52
▸ CA2 P00918 1/20 0.52
▸ CA9 Q16790 1/20 0.52
▸ NR1H4 Q96RI1 1/20 0.51
▸ DNM1 Q05193 1/20 0.51
▸ GPR27 Q9NS67 1/20 0.51
▸ HDAC1 Q13547 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7337469 0.90 PLAU (0.54) NPC1RAB9AMEN1KMT2ATDP1
SCHEMBL7337905 0.86 PABPC1 (0.59) NPC1RAB9AMEN1KMT2ATDP1
SCHEMBL7340329 0.86 PLAU (0.63) DEGS1NPC1RAB9AMEN1KMT2A
SCHEMBL7337325 0.85 PLAU (0.58) DEGS1NPC1RAB9AMEN1KMT2A
SCHEMBL7337311 0.85 PLAU (0.58) DEGS1NPC1RAB9AMEN1KMT2A
SCHEMBL7336457 0.85 NPC1 (0.53) DEGS1NPC1RAB9AMEN1KMT2A
SCHEMBL7340149 0.83 MAOA (0.58) NPC1RAB9A
SCHEMBL7337848 0.83 PLAU (0.67) NPC1RAB9AMEN1KMT2ATDP1
SCHEMBL7336585 0.83 NPC1 (0.59) NPC1RAB9AMEN1KMT2AKDM4E
SCHEMBL7343081 0.82 PLAU (0.67) DEGS1NPC1RAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010049374-A1 Urokinase inhibitors STEELE ANDREW W (US) 2001-12-06 — — US disclosed
US-6284796-B1 NAPHTHAMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-09-04 — — US disclosed
US-6258822-B1 ENZYME INHIBITORS OF NAPHTHALENE AMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-07-10 — — US disclosed
EP-1000018-A2 UROKINASE INHIBITORS Abbott Laboratories (US) 2000-05-17 — — EP disclosed
WO-1999005096-A2 UROKINASE INHIBITORS ABBOTT LABORATORIES (US) 1999-02-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010049374-A1 Urokinase inhibitors SERPINE1, PLAU, SERPINB1 DEGS1 1978/4885NPC1 2478/4885RAB9A 2845/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback